NeurologyLive® Friday 5 — February 9, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Realistic Expectations, Limitations With Gene Therapy for Parkinson Disease: Ignacio Mata, PhD

The associate professor of neurology at the Cleveland Clinic Learner Institute discussed some of the complexities with genetics in Parkinson disease and the ideas behind developing and administering targeted gene therapies. [WATCH TIME: 4 minutes]

2: Understanding the Disconnect Between Trials of Duchenne Therapies and Real-World Data: Dongzhe Hong, PhD

The postdoctoral research fellow at Brigham and Women’s Hospital and Harvard Medical School provided answers to a recently published study highlighting the burden of care and infrequent use of novel exon-skipping drugs for Duchenne in clinical settings. [WATCH TIME: 3 minutes]

3: The Stressed Importance of MS Center Care and Multidisciplinary Teams in Multiple Sclerosis: Marisa McGinley, DO

The staff neurologist at Cleveland Clinic’s Mellen Center for MS detailed some of the negative impacts issues with access to neurologists and MS care centers can have on patient diagnosis and longterm prognosis. [WATCH TIME: 4 minutes]

4: NeuroVoices: Joe Burnett, on FDA Clearance of SmartFrame OR Stereotactic System

In this week's NeuroVoices Q&A, the chief executive officer of ClearPoint Neuro provided clarity on how the recently approved SmartFrame system can enhance the efficiency of operating room procedures, allowing for flexible workflows and image-based corrections.

5: Practical Considerations for the Use of Neurofilament Light Chain and MRI

In episode 7 of the "CMSC Consensus Panel Guidance on the Use of Serum Neurofilament Light Chain in the Management of Multiple Sclerosis" video series, Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, raise important questions about the extent to which biomarkers can aid in patient care as well as their limitations.